Clinical trials: COVID, Coronavirus
Post-COVID Condition
Supervised Computerized Active Program for People With Post-COVID Syndrome (SuperCAP Study)
SuperCAP study is a project aimed at designing and implementing an online program for improvement of cognitive, emotional, and functional status in post-COVID condition.
- Trial name
- SuperCAP (NCT06315894)
- Testing
- SuperCAP Program
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Covid19
Rehabilitation Program for the Sequelae of COVID 19 Infection
SUBPROJECT 1: Describe the situation of post-Covid patients in terms of muscle (skeletal and respiratory), cognitive, emotional and health-related quality of life in the 1st visit of the multidisciplinary post-covid…
- Trial name
- ISIS (NCT04852718)
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS Coronavirus (SARS-CoV-2) Infection
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
- Trial name
- NCT04351503
- Testing
- Study A, Study B, Study C
- Where
- 6 sites in Switzerland
- Volunteers
- 126,586 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hyposmia, COVID-19
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
Olfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfunction after an olfactory training (OT).
- Conditions
- Hyposmia, COVID-19, Parosmia, Anosmia
- Trial name
- OTTODC19 (NCT05384561)
- Testing
- Smell training
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Université du Québec à Trois-Rivières
COVID-19 Prevention
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same…
- Trial name
- SPUTNIK-LIGHT (NCT04741061)
- Testing
- Sputnik Light
- Where
- 15 sites in Russia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
IMMUNOTHERAPY
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
Out of 49 early-stage critically-ill COVID-19 patients, 21 patients are the experimental group who take convalescent plasma compared to 28 patients receive only conventional therapy without taking Convalescent plasma.
- Trial name
- NCT04441424
- Testing
- Convalescent plasma, Hydroxychloroquin with Azithromycin
- Where
- Iraq
- Volunteers
- 49 people
- Sponsor
- Alkarkh Health Directorate-Baghdad
Novel Coronavirus Pneumonia
Study for Novel Coronavirus Pneumonia (NCP)
To develop practical and effective clinical diagnosis and treatment schemes for the control of novel coronavirus pneumonia.
- Trial name
- NCT04283396
- Testing
- systemic treatment
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Coronavirus, COVID
Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France
Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection.
- Conditions
- Coronavirus, COVID, Infection Viral
- Trial name
- INCOVPED (NCT04336761)
- Testing
- nasopharyngeal swab
- Where
- 6 sites in France
- Volunteers
- 901 people
- Sponsor
- University Hospital, Lille
SARS-CoV-2 Infection, Influenza A
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
- Trial name
- CorDx 4in1 (NCT07875270)
- Testing
- Flu A/B/COVID-19 + RSV Multiplex Rapid Test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorDx, Inc.
Covid19
COVID-19 Nasal Swab Trial
The purpose of this trial is to compare 2 types of nasonasopharyngeal swabs (a new design to a conventional nylon-flocked nasopharyngeal swab) for effectiveness.
- Trial name
- NCT04649424
- Testing
- CanSwab
- Where
- 2 sites in Canada
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Orthopaedic Innovation Centre
Covid19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
- Trial name
- ASPIRE (NCT04557046)
- Testing
- Nasal Swab, Nasopharyngeal swab, Throat swab
- Where
- 7 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- LumiraDx UK Limited
Cancer, COVID
Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19
Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference…
- Trial name
- ONCOVID-21 (NCT04510454)
- Testing
- Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Leon Berard
SARS-COV2 Infection, COVID-19 Disease
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Effect of Covid-19 disease in clotting factors levels in hospitalized patients
- Conditions
- SARS-COV2 Infection, COVID-19 Disease, Hospitalized Patients
- Trial name
- NCT04787510
- Testing
- low molecular weight Heparin as standard of care treatment
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University Hospital, Ioannina
COVID-19
Clinical and Biological Predictors of COVID-19 Disease in Older Patients
The project is an observational, prospective study. Its aim is to deepen our understanding of COVID-19 in older patients hospitalized and diagnosed with COVID-19.
- Trial name
- NCT04348396
- Where
- 3 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Long COVID, Long COVID-19
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple…
- Conditions
- Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
- Trial name
- NCT06404086
- Testing
- Modafinil, Solriamfetol, Melatonin
- Where
- 47 sites in United States
- Volunteers
- 830 people
- Sponsor
- Duke University
COVID
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients.
- Trial name
- NCT04428073
- Testing
- Covax-19™
- Volunteers
- 32 people
- Sponsor
- GeneCure Biotechnologies
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at…
- Trial name
- NCT04405466
- Testing
- Blood sampling, Throat swab
- Where
- Germany
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- Miltenyi Biomedicine GmbH
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.